Position paper
27 Oct 2025
Policy considerations for the development, regulation and adoption of biosimilars
Biosimilars can play a role in expanding patient access to biological medicines and in supporting the sustainability of healthcare systems. To fully realize this potential, IFPMA recommends the adoption of a series of policy recommendations.
Read more
Statement
14 Oct 2025
78th Session of the WHO Regional Committee for South-East Asia on primary health care and universal health coverage
On 14 October 2025 in Colombo, Sri Lanka, IFPMA delivered a statement on primary health care (PHC) and universal health coverage (UHC) at the 78th Session of the WHO Regional Committee for South-East Asia. IFPMA welcomes the agenda items on PHC and UHC. Unlocking investment in primary care is critical if we are to build...
Read more
Statement
5 Sep 2025
Statement on the publication of the 24th WHO Model List of Essential Medicines
Responding to the publication of the updated WHO Model List of Essential Medicines (EML), IFPMA Director General, Dr. David Reddy said: “The inclusion of innovative medicines on the updated EML highlights how scientific advances are transforming how we prevent, treat and cure disease, and reinforces the importance of ensuring patients everywhere can benefit from them. ...
Read more
